NIH HEAL Initiative: Results from Selected NIDA Clinical Trials Network Studies
-
Register
- Non-Member - $39
- Regular Member - $29
- Retired - $29
- Early Career Physician - $29
- Resident - $19
- Student - $19
- Associate - $19
- ASAM Staff - Free!
- International Member - $29
- Emeritus Member - $29
- Provisional Member - $29
- Fellow Member - $29
- Honorary Member - $29
- CRT Member - $29
NIH HEAL Initiative: Results from Selected NIDA Clinical Trials Network Studies
Recorded: Thursday, April 24, 2025 to Sunday, April 27, 2025
On-Demand Session
Overview
This 75-minute on-demand session from the ASAM 56th Annual Conference addresses the eligibility and benefits of 7-day extended release buprenorphine, insights from the CTN-0097 trial on extended release naltrexone, and approaches to collaborative care for opioid use disorder in primary care.
This session will provide results from three large multi-site trials conducted in the CTN funded by the HEAL Initiative: The feasibility of a 7-day injectable XR-buprenorphine in ED settings for those who present with minimal to mild opioid withdrawal symptoms: The successful initiation of XR-naltrexone for OUD using a rapid procedure in hospitalized patients ; and A collaborative care model for adult primary care patients with risky opioid use in preventing progression to moderate or severe OUD.
The target audience for this Intermediate level session includes physicians, nurse practitioners, physician assistants, other clinicians, researchers, residents, fellows, students, and counselors.
This session addresses the following ACGME Competencies: Patient Care and Procedural Skills, Medical Knowledge.
This session addresses the following IPEC Competencies: Roles and Responsibilities, Teams and Teamwork.
Learning Objectives
- Upon completion the participant will be able to identify patients with OUD eligible for 7-day extended release buprenorphine and discuss advantages for use.
- Upon completion, the participant will be able to describe the rapid procedure for extended release naltrexone including implications to be learned from the implementation of the procedure in the CTN-0097 trial
- Upon completion, participants will be able to describe the elements of a collaborative care model for patients with subthreshold opioid use disorder, and understand about managing patients with risky opioid use in primary care
Registration Rates
| Rate Description | Rate |
| ASAM Member | $29 |
| Non-Member | $39 |
| Associate Member | $19 |
| Resident Member* | $19 |
| Student Member* | $19 |
*Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.
Membership Question? Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.
Refunds & Cancellations
All ASAM eLearning Center refund requests must be made in writing to education@asam.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or e-Learning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.
Registration Open: 05/26/2025 - 04/26/2028
User Access Closed: 05/26/2028
Course Instructions
- Click on the Contents tab to watch the on-demand recording.
- Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 4 out of 5 questions correctly.
- Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
- Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.
- For Pharmacists ONLY: Complete the task entitled "Enter Pharmacist CPE Monitor Information (Pharmacists Only)". Pharmacists must claim credit and provide their eProfile ID and Birthdate via the Pharmacist CPE Monitor Information survey within 30 days of completing the activity. ASAM will not report CPE Credits claimed 30+ days after activity completion to ACPE. ASAM will not report CPE Credits without accurate and complete information. Courses offering CPE Credit will indicate the amount of credit available for pharmacists on the Credits & Disclosure Tab.
Need Assistance?
For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org
ASAM is proud to offer Essential Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.
Geetha A. Subramaniam
MD, DFAPA, DFAACAP
Geetha A. Subramaniam, MD, DFAPA, DFAACAP is the Deputy Director of the Center for Clinical Trials Network, at NIDA. In this role, she has been instrumental in developing research projects in a variety of topic areas, including addressing the prevention of substance abuse in adolescents, prevention and intervention of prescription stimulant misuse in youth. Previously, she was a full-time faculty member in the Division of Child Psychiatry at Johns Hopkins School of Medicine and the Associate Medical Director of Mountain Manor Treatment Center, Baltimore, MD, where she led clinical trials with adolescents with SUD and served as a preceptor to residents and fellows. She distinguished herself as a clinical and research expert in the assessment and treatment of adolescents and young adults with opioid use disorders. She is ABPN certified in General, Child, and Adolescent, and Addiction Psychiatry and a Distinguished Fellow of both the American Psychiatric Association and the American Academy of Child and Adolescent Psychiatry.
No relevant financial disclosures.
Jennifer McNeely, MD, MS
Associate Professor
NYU Grossman SOM
Jennifer McNeely, MD, MS is Associate Professor at the NYU School of Medicine in the Department of Population Health and Department of Medicine, Division of General Internal Medicine, and Co-Director of the Section on Tobacco, Alcohol, and Drug Use. Dr. McNeely’s research focuses on improving the identification and treatment of unhealthy substance use in general medical settings. Her NIH/NIDA-funded research focuses on health care contacts as an opportunity to identify and provide effective interventions to address drug and alcohol use, and includes studies of screening instruments, hospital addiction consult services, clinical decision support tools for brief intervention, peer navigation for secondary prevention of opioid overdose, and collaborative care to prevent opioid use disorder. Her screening tool validation studies provided evidence for the 2019 USPSTF review of screening for illicit drug use. Dr. McNeely is a general internist specialized in Addiction Medicine, and currently practices at Bellevue Hospital.
No relevant financial disclosures.
Kathryn Hawk, MD, MHS
Associate Professor
Yale University
Kathryn Hawk, MD, MHS is an attending physician in the Yale New Haven Hospital Emergency Department and an Associate Professor in the Department of Emergency Medicine, the Yale School of Public Health and the Program in Addiction Medicine. She was a National Institute on Drug Abuse (NIDA) K12 sponsored Drug use, Addiction and HIV Research (DAHRS) Scholar, and is board certified in emergency and addiction medicine. She completed her residency training and research fellowship in the Yale University Department of Emergency Medicine. Her research primarily focuses on the design, testing and implementation of evidence based-care for ED patients with substance use disorders, with an emphasis on initiating medications for opioid and alcohol use disorder in the ED and maximizing effective linkage to ongoing treatment using innovative strategies. Her research on quality improvement and reducing opioid-associated mortality through data linkages, implementation-facilitation ED-initiated buprenorphine for opioid use disorder, initiating treatment for alcohol use disorder in the ED and the dissemination of evidence-based best practices for care of patients with addiction has been funded by NIDA, the Centers for Disease Control and Prevention (CDC), Emergency Medicine Foundation (EMF), Foundation for Opioid Response (FORE), and the National Institute on Alcohol Abuse and Alcoholism (NIAAA).
No relevant financial disclosures.
Edward Nunes, M.D.
Professor
Columbia U
Dr. Nunes is Professor of Psychiatry at Columbia University Medical Center and New York State Psychiatric Institute (NYSPI), Principal Investigator (multiple PI) of the Greater New York node of the NIDA Clinical Trials Network (CTN), and a practicing psychiatrist Board Certified in Addiction Psychiatry and Addiction Medicine. He has devoted his career to research on the treatment of cocaine, opioid and other substance use disorders and is nationally and internationally recognized for his work on the evaluation and treatment of co-occurring depression, alcohol, cocaine and opioid use disorders and the development of pharmacological and behavioral treatments for substance use disorders as well as his work in the Clinical Trials Network testing the effectiveness of behavioral and pharmacological treatments in community-based treatment settings. Dr. Nunes has extensive experience with research on comorbidity of substance and psychiatric disorders, including co-occurring mood, anxiety disorders and ADHD. He also has extensive experience on the effectiveness and implementation portions of the translational spectrum, including leadership of two large multisite clinical trials in the clinical trials network, one of a computer-delivered behavioral therapy for substance use disorders (Campbell, Nunes et al., 2014) which served as the pivotal trial leading to FDA approval as a digital therapeutic, and one on treatment of opioid use disorder with XR-NTX vs buprenorphine (Lee, Nunes et al., 2019). He has extensive experience mentoring fellows and junior faculty, having recently completed two funding periods of a NIDA-funded K24 with emphasis on mentoring at NYSPI/CUMC and also serves as a national mentor on the Research on Addiction Medicine Scholars program funded by NIDA.
Alkermes: Other Research Support; Braeburn - Camurus: Investigator on multisite trial, Other Research Support
(terminated 12/31/2022); Indivior: Other Research Support; Pear Therapeutics: Other Research Support
Adam Bisaga
Professor of Clinical Psychiatry
Columbia University College of Physicians and Surgeons
Dr. Adam Bisaga is a Professor of Clinical Psychiatry at Columbia University College of Physicians and Surgeons and a Research Scientist at New York State Psychiatric Institute. His NIDA-funded research is focused on development and implementation of new medications and treatment protocols to treat opioid and other substance use disorders. Dr. Bisaga is a member of UN Expert Panel. He contributed to UN and WHO addiction treatment guidances and conducts trainings and addiction treatment program developments internationally. Dr. Bisaga authored more than 100 of peer-reviewed articles, several book chapters, and a book “Overcoming Opioid Addiction“ written for professional and lay audiences. In his commitment to medical education Dr. Bisaga serves as co-director of the SAMHSA-supported “Providers’ Clinical Support System (PCSS)” a national initiative that fosters training of providers and the implementation of effective treatments for opioid use disorders and pain management. His expertise is recognized globally, he is a member of UN Office of Drugs and Crime Expert Panel and a WHO consultant and actively collaborates with United Nations agencies to train healthcare providers and develop international treatment guidelines and programs. Additionally, Dr. Bisaga is at the forefront of integrating technology in addiction healthcare as the Medical Director of Ophelia, a telehealth company specializing in the treatment of opioid use disorder.
Alkermes: Research Grant (Terminated, January 1, 2024); Go Medical: Research Grant (Ongoing); Nirsum Labs:
Consultant/Advisory Board (Ongoing); Sophrosyne: Consultant/Advisory Board (Ongoing)
Accreditation & Credit Designation Statements
Joint Accreditation Statement
In support of improving patient care, the American Society of Addiction Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
The American Society of Addiction Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
This activity awards 1.25 Nursing contact hours.
PAs
ASAM has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1.25 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until 05/06/2028. PAs should only claim credit commensurate with the extent of their participation.
Pharmacists
This activity will offer 1.25 pharmacy contact hours (.125 CEUs). Pharmacists will be asked to provide identifying information (e-Profile ID and DOB in MMDD format) in order to receive credit and allow reporting to CPE Monitor. (UAN: JA0000141-0000-25-021-H01)
Note for pharmacists: Not all courses offer CPE Credit. For courses that do offer CPE Credit, pharmacists must claim credit and provide their eProfile ID and Birthdate via the Pharmacist CPE Monitor Information survey within 30 days of completing the activity.
ASAM will not report CPE Credits claimed 30+ days after activity completion to ACPE. ASAM will not report CPE Credits without accurate and complete information.
Social Workers
As a Jointly Accredited Organization, ASAM is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1.25 general continuing education credits.
IPCE Credit
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change.
California Association for Drug/Alcohol Educators (CAADE)
This educational program is approved by CAADE: #CP40 999 1225.
California Association of DUI Treatment Centers (CADTP)
This educational program is approved by CADTP: #205.
California Consortium of Addiction Programs and Professionals (CCAPP)
This educational program is approved by CCAPP: #OS-20-330-1224.
Other Professions - Continuing Education Credits (CEUs)
Upon completion of the activity and online evaluation, all other participants may request a certificate of participation. Participants may submit this certificate of participation to their professional organization/institute as documentation for completing this accredited continuing activity.
Maintenance of Certification (MOC) or Continuing Certification Programs (CCP)
This activity is designed to meet the requirements for MOC/CCP for several primary physician boards and for state licensing CME requirements. MOC Credit is only reported and designated for ABA, ABIM, ABP and ABS. By completing the online credit claim and evaluation, the learner permits ASAM to report credits to the appropriate Board. Learn more.
American Board of Anesthesiology (ABA)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
American Board of Anesthesiology (ABA)
This activity offers up to 1.25 CME credits, of which 1.25 credits contribute the patient safety CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in AnesthesiologyTM (MOCA®) program, known as MOCA 2.0®. Please consult the ABA website, www.theABA.org, for a list of all MOCA 2.0 requirements.
Maintenance of Certification in Anesthesiology® and MOCA® are registered certification marks of the American Board of Anesthesiology®
American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
American Board of Pediatrics (ABP)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.25 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.
American Board of Preventive Medicine (ABPM)
This activity has been designed to satisfy the Lifelong Professional Development requirements of The American Board of Preventive Medicine’s Continuing Certification (CCP) requirements. These credits are not reported directly to ABPM. Please save your certificate for your records.
American Board of Psychiatry and Neurology (ABPN)
This activity has been designed to satisfy the CME requirements of the American Board of Psychiatry and Neurology’s Continuing Certification (CC) requirements. These credits are not reported directly to ABPN. Please save your certificate for your records.
American Board of Surgery (ABS)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME requirement of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.
Royal College of Physicians and Surgeons of Canada (RCPSC)
The Royal College of Physicians and Surgeons of Canada will recognize activities registered for CME for MOC as meeting the requirements for Royal College MOC Program Section 3 (Self-Assessment Programs) credits. Visit CME that Counts for Royal College MOC for more information.
Disclosure Information
In accordance with the disclosure policies of ASAM and Joint Accreditation, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all accredited continuing education activities. These policies include identifying and mitigating all relevant financial relationships with ineligible companies for those involved in the creation and dissemination of accredited continuing education. Click here to view the full disclosure listing.
Key:
Complete
Next
Failed
Available
Locked